Pafuramidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pafuramidine
Accession Number
DB06532
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • DB-289
Product Ingredients
IngredientUNIICASInChI Key
Pafuramidine MaleateK27F04K3A9837369-26-3SWMNGXODFOCPKQ-BTJKTKAUSA-N
Categories
UNII
H1VG379J2X
CAS number
186953-56-0
Weight
Average: 364.405
Monoisotopic: 364.15354052
Chemical Formula
C20H20N4O3
InChI Key
UKOQVLAXCBRRGH-UHFFFAOYSA-N
InChI
InChI=1S/C20H20N4O3/c1-25-23-19(21)15-7-3-13(4-8-15)17-11-12-18(27-17)14-5-9-16(10-6-14)20(22)24-26-2/h3-12H,1-2H3,(H2,21,23)(H2,22,24)
IUPAC Name
N-methoxy-4-{5-[4-(N-methoxycarbamimidoyl)phenyl]furan-2-yl}benzene-1-carboximidamide
SMILES
CONC(=N)C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(=N)NOC

Pharmacology

Indication

Investigated for use/treatment in pneumonia, trypanosomiasis, malaria, HIV infection, and infectious and parasitic disease (unspecified).

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AgmatineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Agmatine.Experimental, Investigational
AmiodaroneThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Pafuramidine.Approved, Investigational
AmrinoneThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Amrinone.Approved
AranidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Aranidipine.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Azimilide.Investigational
BarnidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Barnidipine.Approved
BencyclaneThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Bepridil.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Bioallethrin.Approved, Experimental
BuspironeThe metabolism of Buspirone can be decreased when combined with Pafuramidine.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Pafuramidine.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Caroverine.Experimental
CilnidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Pafuramidine.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Clevidipine.Approved, Investigational
CyclandelateThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Cyclandelate.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Pafuramidine.Approved, Investigational, Vet Approved
DarodipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Pafuramidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Diltiazem.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Pafuramidine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Pafuramidine.Approved, Investigational
DotarizineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Dotarizine.Investigational
EfonidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Efonidipine.Approved, Investigational
EperisoneThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Eperisone.Approved, Investigational
EthosuximideThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Ethosuximide.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Pafuramidine.Approved
FelodipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Fendiline.Withdrawn
Fish oilThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Fish oil.Approved, Nutraceutical
FlunarizineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Flunarizine.Approved
FluspirileneThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Fluspirilene.Approved, Investigational
FosphenytoinThe serum concentration of Pafuramidine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabapentinThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Gallopamil.Investigational
IsradipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Isradipine.Approved, Investigational
LacidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Lamotrigine.Approved, Investigational
LercanidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Levetiracetam.Approved, Investigational
LidoflazineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Lidoflazine.Experimental
LoperamideThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Loperamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Pafuramidine.Approved
Magnesium sulfateThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Manidipine.Approved, Investigational
MentholThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Menthol.Approved
MethsuximideThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Methsuximide.Approved
MibefradilThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Mibefradil.Investigational, Withdrawn
NaftopidilThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Naftopidil.Investigational
NicardipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nicardipine.Approved, Investigational
NifedipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nitrendipine.Approved, Investigational
NylidrinThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nylidrin.Approved
OtiloniumThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Otilonium.Experimental, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pafuramidine.Approved, Vet Approved
PinaveriumThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Pinaverium.Approved
PrenylamineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with Pafuramidine.Approved, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Pafuramidine.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Pafuramidine.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Pafuramidine.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Pafuramidine.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Pafuramidine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pafuramidine.Approved, Investigational
SeletracetamThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Seletracetam.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Pafuramidine.Approved
SucralfateSucralfate can cause a decrease in the absorption of Pafuramidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Pafuramidine.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Pafuramidine.Approved, Investigational
TerodilineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TranilastThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Tranilast.Approved, Investigational
TrimebutineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Trimethadione.Approved
VerapamilThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Vinpocetine.Investigational
WIN 55212-2The therapeutic efficacy of Pafuramidine can be increased when used in combination with WIN 55212-2.Experimental
ZiconotideThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Pafuramidine.Approved
ZonisamideThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
4586633
ChEMBL
CHEMBL319669
Wikipedia
Pafuramidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedNot AvailableHealthy Volunteers1
2CompletedTreatmentTrypanosoma brucei gambiense infection2
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Interstitial Plasma Cell / Pneumonia, Pneumocystis Carinii1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0663 mg/mLALOGPS
logP2.65ALOGPS
logP2.97ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)8.83ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area103.36 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity145.42 m3·mol-1ChemAxon
Polarizability40.62 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2,5-diphenylfurans. These are organic heterocyclic compounds that contain a furan ring substituted with a phenyl group only the C2- and C5-positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Furans
Sub Class
Diphenylfurans
Direct Parent
2,5-diphenylfurans
Alternative Parents
Benzene and substituted derivatives / Heteroaromatic compounds / Oxacyclic compounds / Amidines / Organooxygen compounds / Hydrocarbon derivatives
Substituents
2,5-diphenylfuran / Benzenoid / Monocyclic benzene moiety / Heteroaromatic compound / Oxacycle / Amidine / Organic nitrogen compound / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on March 19, 2008 10:36 / Updated on June 02, 2018 09:46